Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2006 1
2007 1
2008 4
2010 7
2011 4
2012 3
2013 11
2014 6
2015 18
2016 14
2017 9
2018 6
2019 5
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Results by year
Filters applied: . Clear all
Page 1
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Kaufman B, et al. Among authors: stemmer sm. J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3. J Clin Oncol. 2015. PMID: 25366685 Free PMC article. Clinical Trial.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Hortobagyi GN, et al. Among authors: stemmer sm. N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717303 Free article. Clinical Trial.
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B. Domchek SM, et al. Among authors: stemmer sm. Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23. Gynecol Oncol. 2016. PMID: 26723501 Free PMC article. Clinical Trial.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Zhu AX, et al. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Lancet Oncol. 2015. PMID: 26095784 Clinical Trial.
Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature.
Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM, Salamon F. Bielopolski D, et al. Among authors: stemmer sm. J Chemother. 2017 Apr;29(2):113-117. doi: 10.1179/1973947815Y.0000000029. Epub 2016 Apr 25. J Chemother. 2017. PMID: 25978147 Review.
The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy.
Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, Stemmer SM, Whitesell L, Lindquist S. Scherz-Shouval R, et al. Among authors: stemmer sm. Cell. 2014 Jul 31;158(3):564-78. doi: 10.1016/j.cell.2014.05.045. Cell. 2014. PMID: 25083868 Free PMC article.
Zer A, Rapson Y, Stemmer SM. Zer A, et al. Among authors: stemmer sm. J Thorac Oncol. 2013 May;8(5):662-3. doi: 10.1097/JTO.0b013e3182843a10. J Thorac Oncol. 2013. PMID: 23584299 Free article. No abstract available.
Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M. Perez S, et al. Among authors: stemmer sm. PLoS Genet. 2019 Jun 19;15(6):e1008181. doi: 10.1371/journal.pgen.1008181. eCollection 2019 Jun. PLoS Genet. 2019. PMID: 31216276 Free PMC article.
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, Park JO, Ramirez RA, Abad DG, Feliu J, Muñoz A, Ponz-Sarvise M, Peled A, Lustig TM, Bohana-Kashtan O, Shaw SM, Sorani E, Chaney M, Kadosh S, Vainstein Haras A, Von Hoff DD, Hidalgo M. Bockorny B, et al. Among authors: stemmer sm. Nat Med. 2020 Jun;26(6):878-885. doi: 10.1038/s41591-020-0880-x. Epub 2020 May 25. Nat Med. 2020. PMID: 32451495 Clinical Trial.
Brain metastasis in gastroesophageal adenocarcinoma and HER2 status.
Limon D, Gal O, Gordon N, Katz L, Perl G, Purim O, Amit L, Stemmer SM, Kundel Y, Ben-Aharon I, Brenner B, Siegal T, Yust-Katz S. Limon D, et al. Among authors: stemmer sm. J Neurooncol. 2018 Jun;138(2):315-320. doi: 10.1007/s11060-018-2798-4. Epub 2018 Feb 10. J Neurooncol. 2018. PMID: 29429124
89 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page